Skip to main content

Metastatic Cancer clinical trials at UC Irvine

4 in progress, 2 open to eligible people

Showing trials for
  • Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

    open to eligible people ages 18 years and up

    This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

    Orange, California and other locations

  • Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

    open to eligible people ages 18-100

    This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

    Orange, California

  • A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

    Sorry, not yet accepting patients

    This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

    Orange, California

  • Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

    Orange, California and other locations

Our lead scientists for Metastatic Cancer research studies include .

Last updated: